In a wide-ranging discussion, the two leaders touched upon vaccine development, infant mortality, US education, research funding, machine learning, and precision medicine.
The agreement with PerkinElmer's Wallac Oy subsidiary will bring Mobidiag's real-time PCR-based gastrointestinal tests to a new market.
Researchers implemented qPCR on TaqMan Array Cards to find six pathogens are responsible for up to 90 percent of childhood diarrhea at seven sites in Africa and Asia.
The partners will focus on sequencing and analyzing bacteria and viruses that cause a number of diseases as well as those that make up human microbiomes.
NEW YORK (GenomeWeb) – Diarrheal disease in children from developing countries seems to coincide with broad changes in the composition of microbial communities in the children's guts, according to a study in Genome
NEW YORK (GenomeWeb) – BioMérieux today announced that BioFire's FilmArray Gastrointestinal Panel has received 510(k) clearance for marketing by the US Food and Drug Administration.
NEW YORK (GenomeWeb News) – Nanosphere today announced that the US Food and Drug Administration has cleared its test for the detection of gram-negative bacteria that cause bloodstream infections.
Using Roche 454 sequencing, a team of Swedish researchers has produced the draft genome of a giardiasis-causing parasite.
The Ottawa Institute of Systems Biology is still getting its momentum going, but it's already seen promising work in proteomics and spawned collaborations among its members.
Pharmacogenomics studies presented at the American Association for Cancer Research's annual meeting in Denver, Colo.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.